Be Biopharma has raised $92 million to support the first-in-human Phase 1/2 trial of BE-101, which is made to lower bleeding ...

Columnist Jennifer Lynne interviews Debbie Murray, a New Yorker whose hemophilia B diagnosis didn't occur until she was almost 51.

Now that his adult sons are managing their own hemophilia care, columnist Joe MacDonald is able to consider moving for a job.

Sangamo Therapeutics will regain full rights to develop and market giroctocogene fitelparvovec, a gene therapy candidate for adults with moderately severe to severe hemophilia A, after Pfizer decided ...

Observing her husband, columnist Alliah Czarielle sees that getting older is a great equalizer, as more in their community have health woes.